Wockhardt Q1 FY27 PAT at ₹107 Cr, Revenue Surges 26% to ₹929 Cr
Wockhardt's Q1 FY27 PAT surged to ₹107 crore from a loss of ₹108 crore in Q1 FY26. Revenue grew 26% to ₹929 crore, and EBITDA increased 86% to ₹188 crore. Biotech operations grew 112% to ₹236 crore. Key product Zaynich® received US FDA approval.
The strong financial performance, including a return to profitability and robust revenue growth, coupled with significant product development milestones like US FDA approval for Zaynich®, is expected to have a high impact on the company's market standing and investor sentiment.
The company reported a significant turnaround in profitability with a substantial increase in PAT and revenue, along with strong growth in its biotech segment and positive developments in key product approvals.
Wockhardt Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a Profit After Tax (PAT) of ₹107 crore for Q1 FY27, a significant turnaround from a loss of ₹108 crore in the same quarter last year.
Total revenue for Q1 FY27 grew by 26% to ₹929 crore, compared to ₹738 crore in Q1 FY26. EBITDA also saw a substantial increase of 86%, reaching ₹188 crore from ₹101 crore in the previous year. EBITDA margins improved to 20.2% from 13.7% year-on-year.
The company's overall Biotech operations for the quarter stood at ₹236 crore, marking a growth of 112% compared to Q1 FY26. This growth was driven by the Emerging Market biotech segment, which grew by approximately 146%, fueled by accelerated business opportunities and new deal acquisitions. India Biotech operations also continued to show double-digit growth.
Region-wise, the India Branded Business grew by 21% to ₹156 crore. The UK region reported ₹343 crore with 10% growth, while the Emerging Markets region saw a robust 64% growth to ₹263 crore, primarily driven by the Biotech Insulin segment. The Irish region contributed ₹64 crore with 28% growth.
In terms of product development, Wockhardt reported progress on its novel antibiotics. Zaynich® received approval from the US FDA on May 30 for cUTI and is progressing in the EMA review process. Emrok®/Emrok O® continued to show a growth rate of 29% and is on track to become a leading brand in the anti-MRSA therapy segment. Miqnaf® Nafithromycin has been approved and launched in India, with the removal of a supply condition facilitating wider market access. Foviscu® (WCK 4282) completed its India Phase 3 Clinical Trial, with an NDA filing planned for Q3 FY27.
The company also reported 12 filings, 9 approvals, and 5 launches in its International Business during the quarter. Wockhardt filed one patent during the quarter, bringing its cumulative filings to 3291 and holding 859 patents.
What to do with a filing like this
Wockhardt Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wockhardt Limited. Read the original for the full detail.